source
- OrbiMed secures $3 billion for new life science funds, with over $1 billion earmarked for AsiaOrbiMed, a leading global investor in life science companies, announced the closing of two new funds that together total about $3 billion. The capital will be deployed across a range of private equ…
- Vanda halts Novartis-originated social anxiety drug after Phase 3 missVanda Pharmaceuticals announced it is suspending development of VQW-765, a social anxiety disorder candidate licensed from Novartis, after the drug failed to demonstrate a statistically significant…